Recombinant Human LILRA4/CD85g/ILT7 Protein, CF Summary
Product Specifications
Glu24-Asn446, with a C-terminal 6-His tag
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
8914-T4
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 100 μg/mL in PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
View Larger
When Recombinant Human LILRA4/CD85g/ILT7 is coated at 1 µg/mL, Recombinant Human Angiopoietin-like Protein 7/ANGPTL7 (Catalog # 914-AN) binds with an ED50 of 20-120 ng/mL.
Reconstitution Calculator
Background: LILRA4/CD85g/ILT7
LILRA4, also known as ILT7 and CD85g, is an approximately 60-70 kDa variably glycosylated transmembrane protein that regulates immune cell activation (1). Mature human LILRA4 consists of a 423 amino acid (aa) extracellular domain (ECD) with four immunoglobulin-like domains, a 21 aa transmembrane segment, and a 32 aa cytoplasmic domain (2). Alternative splicing generates an additional isoform that lacks the signal peptide and a portion of the first Ig-like domain. LILRA4 is expressed on plasmacytoid dendritic cells (pDC) but is down-regulated in response to TLR9 signaling (3-5). Antibody mediated crosslinking of LILRA4 on pDC inhibits the production of type I interferons following TLR7 or TLR9 stimulation (3, 4, 6). It also blocks the up-regulation of CCR7 but enhances the up-regulation of Integrin beta 7 on TLR7/9-stimulated pDC (6). LILRA4 associates with the ITAM-containing adaptor protein Fc epsilon RI gamma (3, 4, 6), and this complex binds to cell surface BST2/Tetherin which is expressed on monocytes, plasmacytoid and myeloid dendritic cells, B cells, and activated CD4+ and CD8+ T cells (5, 8). This interaction inhibits the TLR-induced pDC production of type I interferons, IL-6, and TNF-alpha (8).
- Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
- Young, N.T. et al. (2001) Immunogenetics 53:270.
- Cho, M. et al. (2008) Int. Immunol. 20:155.
- Cao, W. et al. (2006) J. Exp. Med. 203:1399.
- Tavano, B. et al. (2013) J. Immunol. 190:2622.
- Tsukamoto, N. et al. (2009) Clin. Cancer Res. 15:5733.
- Tavano, B. and A. Boasso (2014) PLoS ONE 9:e89414.
- Cao, W. et al. (2009) J. Exp. Med. 206:1603.
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human LILRA4/CD85g/ILT7 Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human LILRA4/CD85g/ILT7 Protein, CF and earn rewards!
Have you used Recombinant Human LILRA4/CD85g/ILT7 Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
